A Medical Food Formulation of Griffonia simplicifolia/Magnesium for Childhood Periodic Syndrome Therapy: An Open-Label Study on Motion Sickness

Background Motion sickness (MS) is a disabling condition dominated by disagreement between visually perceived movement and the vestibular system's sense of movement, with symptoms like dizziness, fatigue, and nausea and other autonomic disabling symptoms. Preparations of Griffonia simplicifolia, containing high concentrations of 5-HTP, might be effective for serotonin-related disorders including MS. Therefore, the aim of the present study is to assess the efficacy and safety of Griffonia simplicifolia/Magnesium complex in a pediatric population with MS. Methods Griffonia/ Magnesium complex (50 mg and 200 mg, respectively) was orally administered as prophylactic therapy for MS twice a day for 3 months to Group A and no therapy for MS was administered to the Group B. The MS clinical signs were recorded by parents or where possible directly from children by a specific module included validated questions for the diagnosis that were administered to all subjects and parents of both groups. Results Two study groups were matched for age (p=0.224) sex (p=0.801) and z-BMI (p=0.173). At T0 all recruited subjects in both groups complained about MS. After 3 months (T1) Group A showed an MS prevalence of 36%, significantly lower than MS prevalence in Group B (73%) (p<0.001). Conclusions The findings of the present study suggest the role of Griffonia/Magnesium complex as a potential treatment with middle-term efficacy even for motion sickness.

Motion sickness (MS) is a disabling condition dominated by disagreement between visually perceived movement and the vestibular system's sense of movement, with symptoms like dizziness, fatigue, and nausea, and other autonomic disabling symptoms. Preparations of Griffonia simplicifolia, containing high concentrations of 5-HTP, might be effective for serotonin-related disorders, including MS. Therefore, the aim of the present study is to assess the efficacy and safety of the G. simplicifolia/magnesium complex in a pediatric population with MS. The Griffonia/magnesium complex (50 and 200mg, respectively) was orally administered as a prophylactic therapy for MS twice a day for 3 months to group A, and no therapy for MS was administered to group B. The MS clinical signs were recorded by parents or, where possible, directly from children by a specific module, which included validated questions for the diagnoses that were administered to all subjects and parents of both groups. Two study groups were matched for age (P=.224), sex (P=.801), and z-score body-mass index (P=.173). At T0, all recruited subjects in both groups complained about MS. After 3 months (T1), group A showed an MS prevalence of 36%, significantly lower than MS prevalence in group B (73%) (P<.001). The findings of the present study suggest the role of the Griffonia/magnesium complex as a potential treatment with middle-term efficacy even for MS.